June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Subretinal Transient Hyporeflectivity in Neovascular Age-Related Macular Degeneration and Its Response to Aflibercept
Author Affiliations & Notes
  • Andrea Montesel
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Raheeba Pakeer Muhammed
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Swati Chandak
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Sridevi Thottarath
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Shruti Chandra
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
    Institute of Ophthalmology, University College London, United Kingdom
  • Sobha Sivaprasad
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
    Institute of Ophthalmology, University College London, United Kingdom
  • Footnotes
    Commercial Relationships   Andrea Montesel None; Raheeba Pakeer Muhammed None; Swati Chandak None; Sridevi Thottarath None; Shruti Chandra None; Sobha Sivaprasad Bayern, Novartis, Allergan, Roche, Boehringer Ingelheim, Optos, EyeBiotech, Apellis, Code F (Financial Support)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2160. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Andrea Montesel, Raheeba Pakeer Muhammed, Swati Chandak, Sridevi Thottarath, Shruti Chandra, Sobha Sivaprasad; Subretinal Transient Hyporeflectivity in Neovascular Age-Related Macular Degeneration and Its Response to Aflibercept. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2160.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Subretinal transient hyporeflectivity (STHR) is a novel optical coherence tomography (OCT) finding in age-related macular degeneration (AMD). We described the prevalence of STHR in exudative neovascular AMD (nAMD) and treatment response to aflibercept loading phase.

Methods : Treatment-naïve nAMD patients who completed a loading phase of aflibercept were investigated. OCT scans captured at baseline and after the loading phase were graded for presence of STHR, defined as a small, well-defined, round, subretinal, hyporeflective lesion, delimited between the ellipsoid zone and the retinal pigment epithelium/Bruch membrane complex. Other OCT parameters recorded were macular neovascularisation (MNV) subtypes, location of retinal fluids (intraretinal fluid, IRF, and subretinal fluid, SRF), central retinal thickness (CRT) and central choroidal thickness (CCT). Response was defined as absence of IRF and SRF. Factors associated with completely resolved STHR versus persistent STHR post-loading phase were compared.

Results : 1074 eyes of 1002 patients were included. STHR was observed in 39 eyes of 39 patients, with an estimated prevalence of 3.63% (95% CI 2.59-4.93%). 20 eyes were associated with type 1 MNV (51%), 14 with type 2 (36%), and 5 with type 3 (13%). At baseline, a total of 171 STHR lesions were present, ranging between 1-22 per eye. 9 eyes (23%) had single STHR while 30 eyes (77%) showed multiple STHR. STHR was located extrafoveally in all eyes and two eyes (5.1%) had STHR also in the foveal region.
The total number of STHR reduced significantly after the loading phase to 84 (p =.006). Complete disappearance of STHR was seen in 24 eyes (62%) and persistent STHR in the rest (15/39, 38%, p =.237). No statistically significant differences were found in baseline characteristics (CRT, CCT, presence of fluid subtypes, MNV subtypes) between eyes with resolved and persistent STHR. In eyes with IRF or SRF at baseline, the rates of resolution of STHR were higher in eyes that showed absence of IRF or SRF respectively after the loading phase (p =.046).

Conclusions : Our findings suggest that STHR may represent a marker of low-grade exudation in nAMD eyes, with good response to aflibercept loading phase.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

Type 1 MNV with a temporal area of SRF (A). On the nasal side of the MNV, note the presence of a single STHR. After one injection of aflibercept, note the disappearance of both STHR and SRF.

Type 1 MNV with a temporal area of SRF (A). On the nasal side of the MNV, note the presence of a single STHR. After one injection of aflibercept, note the disappearance of both STHR and SRF.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×